-
1 week ago | 
parkinsonsnewstoday.com | Jamie Askari |Jacob Harney |Mollie Lombardi |Margarida Maia
My family was feeling very helpless and alone after my husband, Arman, was diagnosed with early-onset Parkinson’s disease in 2009. He was only 38 years old then, and we were left floundering for a sense of hope. Soon after his diagnosis, close friends and family members approached me with the idea of fundraising for Parkinson’s disease. This seemed like a great way to contribute to the fight against this disease in my own small way.
-
3 weeks ago | 
parkinsonsnewstoday.com | Jacob Harney |Marisa Wexler |Doc Irish |Jill Hammergren
April is Parkinson’s Awareness Month and, in the U.S. and across the globe this year, patients, caregivers, medical professionals, and advocates will be focusing their attention on helping to empower those living with the neurological disease by providing educational resources, fostering community, and providing opportunities to get involved. World Parkinson’s Day is April 11.
-
4 weeks ago | 
liverdiseasenews.com | Margarida Maia |Jacob Harney |Taayoo Murray |Steve Bryson
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi may be the most effective at reducing itching. Ocaliva (obeticholic acid), which was pulled from the European Union (EU) market and turned down for full approval in the U.S., also reduced markers of liver damage but was linked to new-onset itching and serious side effects.
-
1 month ago | 
hemophilianewstoday.com | Jennifer Lynne |Jacob Harney |Cazandra Campos- MacDonald |Joe MacDonald
There have been many moments in my life when I’ve blatantly thought, “If I die bleeding, I die bleeding.” Of course, I didn’t want to think that, but I felt like I had no other choice. When doctors brush off your bleeding, when you’re told, “You’re “just anemic,” when specialists insist that “women don’t have hemophilia and they aren’t bleeders” — it wears you down. It’s exhausting and infuriating. And for countless women with bleeding disorders, it’s also terrifying.
-
1 month ago | 
liverdiseasenews.com | Andrea Lobo |Jacob Harney |Lindsey Shapiro |Marisa Wexler
A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to technical issues in the production of the medication’s oral capsules. That’s according to a press release from Karolinska Development, a life sciences investment company that holds the majority of Umecrine.
-
1 month ago | 
hemophilianewstoday.com | Jacob Harney |Alliah Czarielle |Jennifer Lynne |Mary Chapman
March is Bleeding Disorders Awareness Month (BDAM), and patients, caregivers, advocates, and supporters are working together to call attention to and provide resources for coping with the bleeding disorders estimated to affect more than 3 million people in the U.S.Bleeding disorders such as hemophilia, von Willebrand disease, and rare clotting factor deficiencies are marked by the body’s inability to form blood clots.
-
2 months ago | 
liverdiseasenews.com | Jacob Harney |Lindsey Shapiro |Margarida Maia |Marisa Wexler
February is Rare Liver Diseases Month, and the Global Liver Institute (GLI) is promoting a series of activities and events to raise awareness of the long list of rare liver diseases, especially in rural areas where healthcare resources and education are limited. GLI is a nonprofit organization that promotes increased awareness and innovation to help improve the lives of those affected by liver disease. The theme of the institute’s annual #RareAware campaign this year is Rare and Rural.
-
Oct 7, 2024 | 
liverdiseasenews.com | Katherine Poinsatte |Jacob Harney |Lindsey Shapiro |Steve Bryson
The U.S. Food and Drug Administration (FDA) has given breakthrough therapy designation to denifanstat, Sagimet Biosciences’ investigational oral therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Its status is indicated specifically for the treatment of MASH patients with moderate to advanced liver scarring (fibrosis) and no cirrhosis, or irreversible fibrosis.
-
Oct 4, 2024 | 
liverdiseasenews.com | Margarida Maia |Marisa Wexler |Jacob Harney |Lindsey Shapiro
Ipsen’s Kayfanda (odevixibat) has been approved, under exceptional circumstances, in the European Union (EU) to treat cholestatic pruritus in people with Alagille syndrome, ages 6 months and older. Cholestatic pruritus refers to intense itch, or pruritus, associated with cholestasis, that is, slowed or stalled flow of the digestive fluid bile, that results in bile building up in the liver and leaking into the blood. “Today’s decision is … very welcome.
-
Oct 3, 2024 | 
liverdiseasenews.com | Jacob Harney |Jay Sandstrom |Lindsey Shapiro |Patricia Inacio
October is National Liver Awareness Month, and the American Liver Foundation (ALF) is promoting a series of activities and events to call attention to liver diseases and raise funds for research. The foundation offers a liver health quiz, available in English or Spanish, to help people find out if they are at risk for liver disease. And given that diet is known to influence liver function, the ALF has put together a 30-day meal plan that includes simple recipes.
